Literature DB >> 30455062

The role of sphingolipids in acute kidney injury.

Tess V Dupre1, Leah J Siskind2.   

Abstract

Acute kidney injury (AKI) is most simply defined as the rapid loss of kidney function in a matter of hours to days. AKI can manifest in a number of ways including pre-renal, post-renal, or intrinsic AKI. During acute kidney injury, multiple pathogenic processes are activated including inflammation, cell death, and the generation of reactive oxygen species, just to name a few. Sphingolipids are known to play a role in a number of the pathogenic pathways involved in the pathogenesis of many types of AKI, which suggests a role for sphingolipids in AKI. This short review will discuss the evidence for a role for sphingolipids in AKI.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute kidney injury; Ceramide; Glycosphingolipid; Sphingolipid; Sphingosine

Mesh:

Substances:

Year:  2018        PMID: 30455062     DOI: 10.1016/j.jbior.2018.11.003

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  6 in total

Review 1.  Sphingolipids and Kidney Disease: Possible Role of Preeclampsia and Intrauterine Growth Restriction (IUGR).

Authors:  Rodrigo Yokota; Benjamin Bhunu; Hiroe Toba; Suttira Intapad
Journal:  Kidney360       Date:  2021-01-07

Review 2.  Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease.

Authors:  Rebekah J Nicholson; Marcus G Pezzolesi; Scott A Summers
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-28       Impact factor: 5.555

3.  Lipidomics Reveals Cisplatin-Induced Renal Lipid Alterations during Acute Kidney Injury and Their Attenuation by Cilastatin.

Authors:  Estefanía Moreno-Gordaliza; Maria Dolores Marazuela; Óscar Pastor; Alberto Lázaro; María Milagros Gómez-Gómez
Journal:  Int J Mol Sci       Date:  2021-11-20       Impact factor: 5.923

4.  Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis.

Authors:  Brian Troyer; Jessalyn Rodgers; Bethany J Wolf; James C Oates; Richard R Drake; Tamara K Nowling
Journal:  Metabolites       Date:  2022-02-01

5.  Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury.

Authors:  Sophia M Sears; Tess V Dupre; Parag P Shah; Deanna L Davis; Mark A Doll; Cierra N Sharp; Alexis A Vega; Judit Megyesi; Levi J Beverly; Ashley J Snider; Lina M Obeid; Yusuf A Hannun; Leah J Siskind
Journal:  J Lipid Res       Date:  2022-02-10       Impact factor: 5.922

Review 6.  Recent Progress in the Development of Opaganib for the Treatment of Covid-19.

Authors:  Charles D Smith; Lynn W Maines; Staci N Keller; Vered Katz Ben-Yair; Reza Fathi; Terry F Plasse; Mark L Levitt
Journal:  Drug Des Devel Ther       Date:  2022-07-12       Impact factor: 4.319

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.